middle.news
Imagion Biosystems Secures Positive FDA Feedback for Breast Cancer Trial
9:35am on Tuesday 15th of July, 2025 AEST
•
Healthcare
Read Story
Imagion Biosystems Secures Positive FDA Feedback for Breast Cancer Trial
9:35am on Tuesday 15th of July, 2025 AEST
Key Points
Positive FDA meeting outcome supports Phase 2 trial plans
IND application targeted for Q3 2025 submission
Manufacturing of MagSense HER2 imaging agent accelerated
Dr. William Dooley appointed Principal Investigator
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imagion Biosystems (ASX:IBX)
OPEN ARTICLE